Current research into retatrutide, a dual stimulant for GLP-1 and GIP receptors, are demonstrating encouraging effects in addressing obesity and diabetes second-type diabetes. Preclinical data suggest a novel process https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/